IFNA1 and STING-associated vasculopathy with onset in infancy: Small molecules that inhibit JAKs reduce type I and type II IFN–induced STAT1 phosphorylation (p-STAT1) in CANDLE and SAVI patients in vitro (7, 9), which suggested their potential utility in reducing the IFN signaling and disease manifestations in these patients.